Table 2 Baseline characteristics of participants prior to treatment
Characteristic | SZF, number, central tendency (variability) | Irbesartan, number, central tendency (variability) | All participants, number, central tendency (variability) | p value |
|---|---|---|---|---|
n = xx | n = xx | n = xx | ||
Demographics | ||||
Age (years)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Height (m)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Weight (kg)a | xx (xx) | xx (xx) | xx (xx) | .xx |
BMI (kg/m2)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Female sex (n,%)b | xx (xx%) | xx (xx%) | xx (xx%) | .xx |
Nationality (China, other)b | xx (xx%) | xx (xx%) | xx (xx%) | .xx |
Vital signs | ||||
Heart rate (beats per minute)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Systolic blood pressure (mmHg)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Diastolic blood pressure (mmHg)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Mean arterial pressure (mmHg)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Respiration rate(breath/min)a | xx (xx) | xx (xx) | xx (xx) | .xx |
Drug or constitution allergic history (yes or no)b | xx (xx%) | xx (xx%) | xx (xx%) | .xx |
Comorbid conditions (n%) | ||||
Diabetic retinopathyb | xx (xx%) | xx (xx%) | xx (xx%) | .xx |
… | ||||
Concomitant treatment | ||||
…b | xx(xx%) | xx(xx%) | xx(xx%) | .xx |